Wise, and I fully agree. On top of all that, my favorite aspect of REPR, is the sustainability of the revenues that you can count on automatically recurring every quarter. REPR sells a Freedom60 device. Every time they sell one of these devices, the customer is a customer for life and must buy $300+ worth of tubing sets from REPR every year. Over time, the tubing set revenue is now the majority of the revenue and growing. These tubing sets have very large margins and are highly profitable. So while there's may be some variability in device sales from quarter to quarter (though lately that has been only going up), the tubing set revenue will only go up. It's a really awesome business model.
The wild cards are that they have a new tubing set pending FDA approval that makes the device far easier and more popular, and the other wild cards are that REPR is constantly working with companies testing their device for other medications. CSL-Behring promotes REPR's device for their drug Hizentra that they got FDA approval for last year and that's why in part we're seeing a rapid growth in device sales lately. When another company/drug gets added, REPR sales should further explode. The Freedom60 is the only device of its kind approved by Medicare as well.
News 
Market Data 
Discover 
